Intro

This chapter critically examines the DANFlu-1 trial, highlighting the comparison between high-dose and standard-dose influenza vaccines for patients with chronic kidney disease. It discusses the study's motivations, methodology, and significant findings related to hospitalizations and health outcomes in this demographic.